Agios Pharmaceuticals, Inc. (AGIO): Price and Financial Metrics

Agios Pharmaceuticals, Inc. (AGIO): $33.14

1.19 (+3.72%)

POWR Rating

Component Grades













Add AGIO to Watchlist
Sign Up

Industry: Biotech


of 465

in industry


  • Value is the dimension where AGIO ranks best; there it ranks ahead of 65.67% of US stocks.
  • AGIO's strongest trending metric is Momentum; it's been moving down over the last 155 days.
  • AGIO's current lowest rank is in the Momentum metric (where it is better than 4.1% of US stocks).

AGIO Stock Summary

  • With a price/earnings ratio of 1.07, Agios Pharmaceuticals Inc P/E ratio is greater than that of about only 0.11% of stocks in our set with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, Agios Pharmaceuticals Inc is reporting a growth rate of -582.37%; that's higher than just 3.67% of US stocks.
  • Revenue growth over the past 12 months for Agios Pharmaceuticals Inc comes in at -77.36%, a number that bests only 1.95% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to AGIO, based on their financial statements, market capitalization, and price volatility, are STRO, CRBP, MIST, APTX, and CCCC.
  • Visit AGIO's SEC page to see the company's official filings. To visit the company's web site, go to

AGIO Valuation Summary

  • AGIO's price/earnings ratio is 1.7; this is 95.34% lower than that of the median Healthcare stock.
  • Over the past 99 months, AGIO's price/earnings ratio has gone up 24.6.
  • Over the past 99 months, AGIO's price/sales ratio has gone down 3.2.

Below are key valuation metrics over time for AGIO.

Stock Date P/S P/B P/E EV/EBIT
AGIO 2021-08-31 33.4 1.5 1.7 1.1
AGIO 2021-08-30 32.9 1.5 1.6 1.1
AGIO 2021-08-27 33.7 1.5 1.7 1.1
AGIO 2021-08-26 32.9 1.5 1.6 1.1
AGIO 2021-08-25 33.0 1.5 1.6 1.1
AGIO 2021-08-24 33.0 1.5 1.6 1.1

AGIO Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 17.86%.
  • Its 5 year price growth rate is now at -13.7%.
  • Its 2 year net cashflow from operations growth rate is now at -20.17%.
Over the past 15 months, AGIO's revenue has gone down $141,864,000.

The table below shows AGIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 44.045 -372.624 1,601.685
2021-06-30 78.751 -355.647 1,591.472
2021-03-31 116.098 -306.15 1,587.211
2020-12-31 203.196 -290.759 -327.37
2020-09-30 194.591 -334.973 -332.063
2020-06-30 185.909 -352.355 -339.257

AGIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AGIO has a Quality Grade of C, ranking ahead of 30.92% of graded US stocks.
  • AGIO's asset turnover comes in at 0.051 -- ranking 321st of 681 Pharmaceutical Products stocks.
  • NTLA, NAVB, and JAZZ are the stocks whose asset turnover ratios are most correlated with AGIO.

The table below shows AGIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.051 0.980 1.744
2021-03-31 0.089 0.980 1.725
2020-12-31 0.230 0.986 -0.342
2020-09-30 0.218 0.989 -0.363
2020-06-30 0.221 0.990 -0.424
2020-03-31 0.220 0.991 -0.486

AGIO Price Target

For more insight on analysts targets of AGIO, see our AGIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $63.50 Average Broker Recommendation 1.75 (Moderate Buy)

AGIO Stock Price Chart Interactive Chart >

Price chart for AGIO

AGIO Price/Volume Stats

Current price $33.14 52-week high $62.15
Prev. close $31.95 52-week low $29.21
Day low $31.34 Volume 520,100
Day high $33.26 Avg. volume 448,050
50-day MA $35.76 Dividend yield N/A
200-day MA $47.34 Market Cap 1.80B

Agios Pharmaceuticals, Inc. (AGIO) Company Bio

Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. The company was founded in 2007 and is based in Cambridge, Massachusetts.

AGIO Latest News Stream

Event/Time News Detail
Loading, please wait...

AGIO Latest Social Stream

Loading social stream, please wait...

View Full AGIO Social Stream

Latest AGIO News From Around the Web

Below are the latest news stories about Agios Pharmaceuticals Inc that investors may wish to consider to help them evaluate AGIO as an investment opportunity.

H.C. Wainwright Thinks Agios Pharma’s Stock is Going to Recover

In a report released today, Michael King from H.C. Wainwright reiterated a Buy rating on Agios Pharma (AGIO – Research Report), with a price target of $95.00. The company's shares closed last Monday at $32.22, close to its 52-week low of $29.21. According to, King is a 4-star analyst with an average return of 17.6% and a 49.2% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. Currently, the analyst consensus on Agios Pharma is a Strong Buy with an average price target of $60.75.

Howard Kim on TipRanks | January 10, 2022

Seelaus Asset Management LLC Buys Merck Inc, Eagle Materials Inc, Coinbase Global Inc, Sells ...

Investment company Seelaus Asset Management LLC (Current Portfolio) buys Merck Inc, Eagle Materials Inc, Coinbase Global Inc, Gentherm Inc, ABB, sells Zimmer Biomet Holdings Inc, KKR Inc, U.S.

Yahoo | January 10, 2022

Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases

– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February – – Five Pivotal Clinical Trials are Planned and Ongoing in Thalassemia, Sickle Cell Disease and Pediatric PK Deficiency – – Agios is Expanding Clinical Portfolio with Trials of Novel PK Activator AG-946 – – Strong Cash Position Expected to Enable Execution of Robust Operating Plan to Cash-Flow Positivity – CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Agios

Yahoo | January 10, 2022

Top Small Cap Stocks for January 2022

These are the small cap stocks with the best value, fastest growth, and most momentum for January 2022.

Yahoo | January 7, 2022

Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET.

Intrado Digital Media | December 22, 2021

Read More 'AGIO' Stories Here

AGIO Price Returns

1-mo -2.44%
3-mo -30.35%
6-mo -35.21%
1-year N/A
3-year -40.70%
5-year -21.15%
YTD 0.82%
2021 -24.14%
2020 -9.26%
2019 3.56%
2018 -19.35%
2017 37.00%

Continue Researching AGIO

Want to see what other sources are saying about Agios Pharmaceuticals Inc's financials and stock price? Try the links below:

Agios Pharmaceuticals Inc (AGIO) Stock Price | Nasdaq
Agios Pharmaceuticals Inc (AGIO) Stock Quote, History and News - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.818 seconds.